Loading organizations...
§ Private Profile · San Francisco, CA, USA
Biotech company developing next-generation antibody-drug conjugates (ADCs) for cancer therapeutics, focused on oncology drug development.
Kivu Bioscience is a San Francisco, US-based biotechnology company developing next-generation antibody-drug conjugates (ADCs) for cancer therapeutics. The firm focuses on comprehensive oncology drug development, advancing programs from initial target identification through preclinical studies to potential clinical trials, reflecting a strategic pivot towards innovative biopharmaceutical solutions. Operating as a privately-held entity, Kivu Bioscience receives venture capital backing, with key figures including founder and CEO Mohit Trikha, and investor Edward van Wezel, associated with BGV. Its pipeline is dedicated to addressing unmet needs in oncology by targeting specific tumors with advanced therapeutic modalities. Kivu Bioscience was founded in 2004 by Mohit Trikha. Its business model centers on privately-held biotech, funded through venture capital. The firm focuses on oncology/cancer drugs, biopharmaceutical developments targeting tumors via ADCs.
Kivu Bioscience has raised $92.0M across 1 funding round.
Kivu Bioscience has raised $92.0M in total across 1 funding round.
Kivu Bioscience has raised $92.0M in total across 1 funding round.
Kivu Bioscience's investors include Novo Holdings.
Kivu Bioscience has raised $92.0M across 1 funding round. Most recently, it raised $92.0M Series A in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 28, 2024 | $92M Series A | Novo Holdings | — | Announced |